

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

- *Three oral presentations at the Alzheimer's Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626*

Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer's Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024.

Presentation details (all times are EDT)

Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer

Date: Monday, July 29, 2024 | 2:50 PM – 3:00 PM

Location: Hall A - Pennsylvania Convention Center

Presenter: Tamara Seredenina, PhD (AC Immune)

Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies

Date: Tuesday, July 30, 2024 | 9:40 AM – 9:50 PM

Location: 201 ABC - Pennsylvania Convention Center

Presenter: Emma Fiorini, PhD (AC Immune)

A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer[®]- Antibody Drug Conjugates)

Date: Wednesday, July 31, 2024 | 8:07 AM – 8:14 AM

Location: 118 ABC - Pennsylvania Convention Center

Presenter: Madiha Derouazi, PhD (AC Immune)

Poster details

#18 Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer's disease and Down Syndrome-related Alzheimer's disease

Date: Tuesday, July 30, 2024 | 8:00 AM – 4:15 PM

Location: Exhibit Hall - Pennsylvania Convention Center

Presenter: Michael Rafii, MD, PhD (Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA)

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding in potential milestone payments plus royalties.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

Head of Investor Relations & Corporate Communications

Gary Waanders, Ph.D., MBA
AC Immune
Phone: +41 21 345 91 91
Email: gary.waanders@acimmune.com

U.S. Investors

Corey Davis, Ph.D.
LifeSci Advisors
Phone: +1 212 915 2577
Email: cdavis@lifesciadvisors.com

International Media

Chris Maggos
Cohesion Bureau
Phone: +41 79 367 6254
Email: chris.maggos@cohesionbureau.com

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.